CD4 and myeloid sarcoma: Thus, this analysis identified subpopulations of CD4 T cells that responded similarly to vaccination when comparing patients with MS treated with aCD20 to healthy controls (for example, subsets of activated TH1 cells) as well as circulating TFH cells that had similar initial induction in the two cohorts but poor maintenance in patients with MS treated with aCD20.